Center for Patient Derived Models Services
CPDM hosts and distributes a large, curated Patient-Derived Model Repository spanning brain tumors, hematological malignancies, and solid tumors (including breast, ovarian, pancreatic, colorectal, and more). For projects requiring bespoke systems, our model development team generates patient-derived cell lines (PDCLs) as organoids, spheroids, and 2D cultures, as well as patient-derived xenografts (PDXs), with scalable expansion and secure model banking.
Every model is backed by rigorous characterization — STR authentication, genomics, transcriptomics, and histology — paired with precision oncology research support that includes ex vivo drug testing from fresh patient material or established models, endpoint assays (CTG), phenotypic readouts (Incucyte, Cytation 5), and SMR. We also collaborate on grants and clinical trial support to integrate models, assays, and analytics into study workflows.
Whether you need a model on demand or a customized program, CPDM delivers guidance from intake to data delivery. Explore our services below.
Cancer models generated from patients before, during, or post-clinical trial are valuable resources to study patients' trial responsiveness and could potentially serve as avatars to predict future treatment responsiveness.
Our team of clinical research coordinators offers processes for regulatory compliance to generate cancer models from clinical trial patients.
CPDM supports the creation of patient derived cell lines (2D, 3D spheroid, or organoid); patient derived xenografts (PDX); as well as acute cell sensitivity to drug models (ACSD) from patient tumors.
Contact the Center for Patient Derived Models
Email models@dfci.harvard.edu to learn more about our services and request a quote.
